Post-Transplant Lymphoproliferative Disorder: 2020 Pipeline Insight Report - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Post-Transplant Lymphoproliferative Disorder- Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Post-Transplant Lymphoproliferative Disorder market.

A detailed picture of the Post-Transplant Lymphoproliferative Disorder pipeline landscape is provided, which includes the disease overview and Post-Transplant Lymphoproliferative Disorder treatment guidelines. The assessment part of the report embraces in-depth Post-Transplant Lymphoproliferative Disorder commercial assessment and clinical assessment of the Post-Transplant Lymphoproliferative Disorder pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Post-Transplant Lymphoproliferative Disorder collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

• All of the companies that are developing therapies for the treatment of Post-Transplant Lymphoproliferative Disorder with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Post-Transplant Lymphoproliferative Disorder treatment.
• Post-Transplant Lymphoproliferative Disorder key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Post-Transplant Lymphoproliferative Disorder market.

Scope of the Report

• The Post-Transplant Lymphoproliferative Disorder report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Post-Transplant Lymphoproliferative Disorder across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of Post-Transplant Lymphoproliferative Disorder therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
• Detailed Post-Transplant Lymphoproliferative Disorder research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Post-Transplant Lymphoproliferative Disorder.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Post-Transplant Lymphoproliferative Disorder.
• In the coming years, the Post-Transplant Lymphoproliferative Disorder market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Post-Transplant Lymphoproliferative Disorder R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Post-Transplant Lymphoproliferative Disorder treatment market. Several potential therapies for Post-Transplant Lymphoproliferative Disorder are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Post-Transplant Lymphoproliferative Disorder market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Post-Transplant Lymphoproliferative Disorder) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Topics Covered

1. Report Introduction

2. Post-Transplant Lymphoproliferative Disorder

2.1. Overview

2.2. History

2.3. Post-Transplant Lymphoproliferative Disorder Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Post-Transplant Lymphoproliferative Disorder Diagnosis

2.6.1. Diagnostic Guidelines

3. Post-Transplant Lymphoproliferative Disorder Current Treatment Patterns

3.1. Post-Transplant Lymphoproliferative Disorder Treatment Guidelines

4. Post-Transplant Lymphoproliferative Disorder - Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Post-Transplant Lymphoproliferative Disorder companies collaborations, Licensing, Acquisition - Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Post-Transplant Lymphoproliferative Disorder Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Post-Transplant Lymphoproliferative Disorder Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Post-Transplant Lymphoproliferative Disorder Late Stage Products (Phase-III)

7. Post-Transplant Lymphoproliferative Disorder Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Post-Transplant Lymphoproliferative Disorder Discontinued Products

13. Post-Transplant Lymphoproliferative Disorder Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

14. Post-Transplant Lymphoproliferative Disorder Key Companies

15. Post-Transplant Lymphoproliferative Disorder Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Post-Transplant Lymphoproliferative Disorder Unmet Needs

18. Post-Transplant Lymphoproliferative Disorder Future Perspectives

19. Post-Transplant Lymphoproliferative Disorder Analyst Review

Companies Mentioned

• Atara Biotherapeutics
• Bluebird bio
• Bristol-Myers Squibb
• Xencor, Inc.
• Chiltern International Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/rcjsm6